Regulatory immune cells in regulation of intestinal inflammatory response to microbiota

被引:203
|
作者
Sun, M. [1 ]
He, C. [1 ,2 ]
Cong, Y. [2 ,3 ]
Liu, Z. [1 ]
机构
[1] Tongji Univ, Dept Gastroenterol, Inst Intestinal Dis, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China
[2] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA
[3] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA
基金
中国国家自然科学基金;
关键词
INNATE LYMPHOID-CELLS; ALTERNATIVELY ACTIVATED MACROPHAGES; ACUTE EXPERIMENTAL COLITIS; DELTA T-CELLS; B-CELLS; BOWEL-DISEASE; DENDRITIC CELLS; INTRAEPITHELIAL LYMPHOCYTES; ORAL TOLERANCE; CROHNS-DISEASE;
D O I
10.1038/mi.2015.49
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The intestinal lumen harbors nearly 100 trillion commensal bacteria that exert crucial function for health. An elaborate balance between immune responses and tolerance to intestinal microbiota is required to maintain intestinal homeostasis. This process depends on diverse regulatory mechanisms, including both innate and adaptive immunity. Dysregulation of the homeostasis between intestinal immune systems and microbiota has been shown to be associated with the development of inflammatory bowel diseases (IBD) in genetically susceptible populations. In this review, we discuss the recent progress reported in studies of distinct types of regulatory immune cells in the gut, including intestinal intraepithelial lymphocytes, Foxp3(+) regulatory T cells, regulatory B cells, alternatively activated macrophages, dendritic cells, and innate lymphoid cells, and how dysfunction of this immune regulatory system contributes to intestinal diseases such as IBD. Moreover, we discuss the manipulation of these regulatory immune cells as a potential therapeutic method for management of intestinal inflammatory disorders.
引用
收藏
页码:969 / 978
页数:10
相关论文
共 50 条
  • [21] REGULATION OF IMMUNE RESPONSE AGAINST MYCOBACTERIUM TUBERCULOSIS BY THE POPULATION OF REGULATORY DENDRITIC CELLS
    Rubakova, E. I.
    Kapina, M. A.
    Logunova, N. N.
    Majorov, K. B.
    Apt, A. S.
    INFEKTSIYA I IMMUNITET, 2018, 8 (02): : 169 - 174
  • [22] Regulation of wheat germ polysaccharides in the immune response of mice from newborn to adulthood associated with intestinal microbiota
    Yun, Liyuan
    Li, Wen
    Liu, Yanan
    Wu, Tao
    Zhang, Min
    FOOD & FUNCTION, 2020, 11 (11) : 9662 - 9674
  • [23] Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease
    Cantorna, Margherita T.
    McDaniel, Kaitlin
    Bora, Stephanie
    Chen, Jing
    James, Jamaal
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2014, 239 (11) : 1524 - 1530
  • [24] The Microbiota and epigenetic Regulation of T Helper 17/Regulatory T Cells: in Search of a Balanced immune System
    Luo, Annie
    Leach, Steven T.
    Barres, Romain
    Hesson, Luke B.
    Grimm, Michael C.
    Simar, David
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [25] The regulatory mechanisms of intestinal mucosal immune in inflammatory bowel disease and its response to the treatment with astragaius polysaccharides
    Dai, J. Y.
    Zhu, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 93 - 93
  • [26] Impact of intestinal microbiota on the immune response to Candida albicans colonization
    Kruger, W.
    Vielreicher, S.
    Piskor, E. M.
    Kosan, C.
    Jacobsen, I. D.
    MYCOSES, 2022, 65 : 16 - 16
  • [27] Pathobiology of Salmonella, intestinal microbiota, and the host innate immune response
    Santos, Renato Lima
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [28] Trafficking of regulatory T cells in the intestinal immune system
    Pabst, Oliver
    INTERNATIONAL IMMUNOLOGY, 2013, 25 (03) : 139 - 143
  • [29] Immune Cells and Microbiota Response to Iron Starvation
    Chieppa, Marcello
    Giannelli, Gianluigi
    FRONTIERS IN MEDICINE, 2018, 5
  • [30] The role of NOD2 in intestinal immune response and microbiota modulation: A therapeutic target in inflammatory bowel disease
    Liu, Ziyue
    Zhang, Yaqin
    Jin, Tao
    Yi, Chengxue
    Ocansey, Dickson Kofi Wiredu
    Mao, Fei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113